GU Cancers 2020 | ATLAS update: rucaparib for bladder cancer

VJOncology is committed to improving our service to you

Petros Grivas

Petros Grivas, MD, PhD, University of Washington, Seattle, WA, outlines the ATLAS study (NCT03397394), which investigated the efficacy of the PARP inhibitor rucaparib in the treatment of urothelial carcinoma. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter